Charlton, GB
David Wesley Charlton, Reading GB
Patent application number | Description | Published |
---|---|---|
20130016514 | DAZZLERSAANM Stacey; Craig DanielAACI WhitchurchAACO GBAAGP Stacey; Craig Daniel Whitchurch GBAANM Charlton; David WesleyAACI ReadingAACO GBAAGP Charlton; David Wesley Reading GB - A dazzler arrangement is disclosed in which the strength of the dazzle beam is modulated in accordance with the range of a target to be dazzled. A stray detection beam is transmitted alongside the dazzle beam to allow detection of a secondary object approaching or at the periphery of the dazzle beam, whereupon the dazzle beam is attenuated or inhibited. | 01-17-2013 |
Henry Charlton, Salisbury GB
Patent application number | Description | Published |
---|---|---|
20080293656 | PROCESSING NUCLEIC ACID - The present invention relates to a method of processing nucleic acid. More particularly, it relates to a method of purifying extra-chromosomal DNA by removing cell debris and/or RNA from a process stream comprising extra chromosomal DNA and a precipitate resulting from preceding cell lysis and/or precipitation reactions. It also relates to nucleic acid, particularly extra chromosomal DNA, purified by a method of the invention; a pharmaceutical composition comprising or consisting of the same and apparatus for said method. | 11-27-2008 |
John Charlton, Lancashire GB
Patent application number | Description | Published |
---|---|---|
20140146508 | SAFETY DEVICE FOR INTERACTIVE DISPLAY SYSTEM - There is disclosed an interactive whiteboard system including a display surface ( | 05-29-2014 |
Julie Anne Charlton, Hexham GB
Patent application number | Description | Published |
---|---|---|
20090005443 | Treatment of Depression - There is described a compound selected from the group consisting of tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof, for the treatment or alleviation of depression. There is also described a method of treating a patient suffering from depression. | 01-01-2009 |
Julie Anne Charlton, Newcastle Upon Tyne GB
Patent application number | Description | Published |
---|---|---|
20100144626 | Treatment of Multi-Drug Resistant Bacterial Infections - There is described an imidazole for the treatment of an infection caused or contributed to by microorganisms resistant to antibiotics. There is also described a method of treating a patient suffering from an infection caused or contributed to by microorganisms resistant to antibiotics, said method comprising the step of administering an effective amount of an imidazole. | 06-10-2010 |
20110039906 | ANTIBACTERIAL COMBINATION THERAPY - There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species. | 02-17-2011 |
Julie Anne Charlton, Tyne & Wear GB
Patent application number | Description | Published |
---|---|---|
20110033376 | Treatment of Melanoma - There is described dexanabinol, or a derivative thereof, for the treatment of melanoma. There is also described a method of treating a patient suffering from melanoma. | 02-10-2011 |
Keith Charlton, Aberdeen GB
Patent application number | Description | Published |
---|---|---|
20090117109 | Methods For Reducing Biofilm Formation In Infectious Bacteria - The present invention provides methods of preventing or inhibiting biofilm formation by a population of bacteria, said method comprising the administration to the population of an antibody to a lactone or lactone-derived signal molecule secreted by bacteria. The invention therefore also provides methods for the treatment of bacterial infection in biofilm formation is prevented or inhibited. | 05-07-2009 |
Keith Alan Charlton, Aberdeen GB
Patent application number | Description | Published |
---|---|---|
20100303831 | Methods For The Treatment Of An Infectious Bacterial Disease With An Anti-Lactone Or Lactone Derived Signal Molecules Antibody - The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant. | 12-02-2010 |
20110027280 | Methods For Inducing Autolysis In Infectious Bacteria - The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacterial cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to | 02-03-2011 |
20130011400 | Methods For Inducing Autolysis In Infectious Bacteria - The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacterial cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to | 01-10-2013 |
20130045208 | Methods for the Treatment of an Infectious Bacterial Disease with an Anti-Lactone or Lactone Derived Signal Molecules Antibody - The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant. | 02-21-2013 |
20140248302 | RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES - A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats. | 09-04-2014 |
20160095910 | SELF-ASSEMBLING SYNTHETIC PROTEINS - The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host. | 04-07-2016 |
Martin David Brian Charlton, Southampton GB
Patent application number | Description | Published |
---|---|---|
20120112165 | Optical Device - An improved optoelectronic device is described, which employs optically responsive nanoparticles and utilises a non-radiative energy transfer mechanism. The nanoparticles are disposed on the sidewalls of one or more cavities, which extend from the surface of the device through the electronic structure and penetrate the energy transfer region. The nanoparticles are located in close spatial proximity to an energy transfer region, whereby energy is transferred non-radiatively to or from the electronic structure through non-contact dipole-dipole interaction. According to the mode of operation, the device can absorb light energy received from the device surface via the cavity and then transfer this non-radiatively or can transfer energy non-radiatively and then emit light energy towards the surface of the device via the cavity. As such, the deice finds application in light emitting devices, photovoltaic (solar) cells, displays, photodetectors, lasers and single photon devices. | 05-10-2012 |
Michael Charlton, Berkshire GB
Patent application number | Description | Published |
---|---|---|
20150333973 | CONTROLLING A SERVER - Method, system and application for controlling a program executing within a server from a mobile device. Capturing information describing a user interaction with a user interface of the mobile device. Determining a next user interaction based on the captured information and data describing the user interface. Triggering an event corresponding to the determined next user interaction. | 11-19-2015 |
Michael Hugh Charlton, Abingdon GB
Patent application number | Description | Published |
---|---|---|
20140010762 | IMAGING AGENTS - An imaging agent for cells which produces an intracellular imaging signal proportional to the amount of hCE-1 in the cells independently of the amount of hCE-2 and/or hCE-3 in the cells, said imaging agent being a covalent conjugate of (a) an imaging agent and (b) an alpha mono- or di-substituted amino acid ester, wherein (a) is directly linked to (b), or (a) is indirectly linked to (b) by a linker radical, and wherein said direct or indirect linkage is via the amino group of (b), and wherein the amino group is not directly linked to a carbonyl group, and wherein the said alpha mono- or di-substituted amino acid ester part is selectively hydrolysable to the corresponding carboxylic acid part by the intracellular carboxylesterase enzyme hCE-1 relative to the intracellular enzymes hCE-2 or hCE-3. | 01-09-2014 |
Michael Hugh Charlton, Oxfordshire GB
Patent application number | Description | Published |
---|---|---|
20100069473 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase - Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: | 03-18-2010 |
20100087515 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS - Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R | 04-08-2010 |
20110039920 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE - Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5(carbamoylamino)-2-thienyl]phenyl}pent-4-enoate; Cyclopentyl 5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-norvalinate; Cyclopentyl(2S,4E)-2-amino-5-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-5-methylphenyl}pent-4-enoate; Cyclopentyl(25,4E)-2-amino-5-{5-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]-2-methylphenyl}pent-4-enoate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl O-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]phenyl}-L-homoserinate; Cyclopentyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate; and tert-Butyl N-{3-[4-carbamoyl-5-(carbamoylamino)-2-thienyl]benzyl}-L-alaninate are hydrolysed to the corresponding carboxylic acids by intracellular carboxylesterases, and are useful for the inhibition of IKKβ activity. | 02-17-2011 |
Patricia Charlton, London GB
Patent application number | Description | Published |
---|---|---|
20080215509 | Content Access Rights Management - An apparatus ( | 09-04-2008 |
Patricia M. Charlton, London GB
Patent application number | Description | Published |
---|---|---|
20080275894 | CONTENT ITEM APPARATUS AND METHOD OF OPERATION THEREFOR - A content item apparatus comprises a content data receiver ( | 11-06-2008 |
20090231128 | METHOD AND APPARATUS FOR ALERT MANAGEMENT - An alert management apparatus ( | 09-17-2009 |
20090254944 | ALERT MANAGEMENT APPARATUS AND A METHOD OF ALERT MANAGMENT THEREFOR - An alert management apparatus ( | 10-08-2009 |
Patricia M. Charlton, Bayswater GB
Patent application number | Description | Published |
---|---|---|
20090164572 | APPARATUS AND METHOD FOR CONTENT ITEM ANNOTATION - An apparatus for content item annotation comprises a user group processor ( | 06-25-2009 |
Rachel Charlton, Bath GB
Patent application number | Description | Published |
---|---|---|
20130216493 | PEG OR PEG BLOCK COPOLYMERS FOR TREATING COLORECTAL CANCER - The present invention relates to methods for and of treating, ameliorating or preventing colorectal cancer (CRC) in humans using polyethylene glycol (PEG) or a PEG block-copolymer such as Pluronic® F68. Compositions for use in treating, ameliorating and/or preventing CRC comprising PEG are also disclosed. Such compositions may be used in the methods of the invention. | 08-22-2013 |
Scott Charlton, Newark GB
Patent application number | Description | Published |
---|---|---|
20100047073 | TURBINE BLADE ASSEMBLY - A turbine blade assembly, in particular of a gas turbine, is provided. The turbine blade assembly includes a turbine disc with rotor blades inserted into notches of the turbine disc and locking plates that are placed inside circular grooves with rims in the turbine disc and in the rotor blade. The edges of the locking plates that are oriented towards the center of the turbine disc are castellated by providing teeth and accordingly a part of the rim of the circular groove of the turbine disc is also castellated by providing gaps and whereby the gaps of the rim match the teeth of the locking plates. The locking plates have a spring-back force to provide both locking and sealing capabilities during engine operation. | 02-25-2010 |
20100178173 | Turbine blade assembly - A turbine blade assembly, which can be used for a gas turbine is provided. The turbine blade assembly includes turbine blades with platforms, gaps between the platforms of adjacent turbine blades and seals. Each seal covers the gap between the platforms of two adjacent turbine blades wherein the platforms are provided with slots extending in the downstream flow direction. The turbine blades have root cavities, wherein the seal covers at least the whole length of the root cavities of two adjacent turbine blades. The seal is formed from a strip and the seal is placed in two opposed slots formed in each of the platforms of two adjacent turbine blades and open towards the respective downstream ends. | 07-15-2010 |
Scott Charlton, Farndon GB
Patent application number | Description | Published |
---|---|---|
20130121839 | TURBINE AIRFOIL AND METHOD FOR THERMAL BARRIER COATING - A turbine airfoil including an airfoil body is disclosed. The airfoil includes a leading edge, a trailing edge, an exterior surface including a suction side extending from the leading edge to the trailing edge and a pressure side extending from the leading edge to a trailing end. The pressure side is located opposite to the suction side on the airfoil body. The complete pressure side of the exterior surface is coated by a thermal barrier coating with a thickness decreasing towards the trailing end. | 05-16-2013 |
Steven Charlton, Consett GB
Patent application number | Description | Published |
---|---|---|
20160106008 | Air Handling Unit and Method of Operating the Same - An air handling unit, particularly for data center cooling, operates to cool a flow of return air from a conditioned space using a flow of ambient air. The return air is recirculated to the conditioned space as supply air. The flow of ambient air can be adiabatically cooled to a lower temperature to provide additional cooling. A flow of makeup air can be joined with the cooled return air to form the supply air, and can be sourced from the ambient environment directly or from the heated flow of ambient air. | 04-14-2016 |
Steven John Charlton, Horsham Sussex GB
Patent application number | Description | Published |
---|---|---|
20150376183 | IP Receptor Agonist Heterocyclic Compounds - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. | 12-31-2015 |
Steven John Charlton, Horsham GB
Patent application number | Description | Published |
---|---|---|
20120183549 | CHEMOKINE RECEPTOR BINDING POLYPEPTIDES - The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2. | 07-19-2012 |
20130102611 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples. | 04-25-2013 |
20130330346 | Chemokine receptor binding polypeptides - The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2. | 12-12-2013 |
20140050736 | CHEMOKINE RECEPTOR BINDING POLYPEPTIDES - The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2. | 02-20-2014 |
20140243346 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples. | 08-28-2014 |
20150376183 | IP Receptor Agonist Heterocyclic Compounds - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. | 12-31-2015 |
Susan Charlton, Castle Cary GB
Patent application number | Description | Published |
---|---|---|
20080213310 | Use of lytic toxins and toxin conjugates - Agents are provided which are capable of inhibiting the cell division cycle in a target cell of interest. The agents comprise first and second components, wherein the first component is a targeting moiety which is capable of directing the second component to the target cell of interest. The second component is capable of inhibiting the cell division cycle in the target cell of interest. The agents are preferably provided in the form of conjugates, and the second component is preferably a cytolethal distending toxin. Methods for the preparation of the agents, and the use thereof for treating proliferative cell disorders and intracellular pathogens are also provided. | 09-04-2008 |